

STIC-ILL

4/10/01

From: Canella, Karen  
Sent: Wednesday, January 21, 2004 3:22 PM  
To: STIC-ILL  
Subject: ill order. PCT/US02/26258

479418

Art Unit 1642 Location Remsen 3A29 (office, I don't know my mail box address yet)

Telephone Number 272-0828

Application Number PCT/US02/26258

1. Scandinavian Journal of Immunology, Mar 2001, 53(3):277-281
2. Journal of Immunotherapy, 1991 Aug, 10(4):267-277
3. International Journal of Cancer:  
1992, Suppl 7, pp. 67-68  
31 Aug 1998, 77(5):763-772
4. Critical Reviews in Immunology, 1992, 12(3-4):101-124
5. Clinical and Experimental Immunology, 1992 Dec, 90(3):368-375
6. Blood, 1993 Sep 15, 82(6):1803-1812
7. Therapeutic Immunology, 1994, 1(5):279-287
8. Leukemia, 1996 Nov, 10(11):1765-1772
9. Experimental Hematology, Aug 1999, 27(8):1264-1270

12845675

10. ~~BIOSIS~~ COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 1989:396927 BIOSIS

DOCUMENT NUMBER: PREV198937063575; BR37:63575

TITLE: THE INDUCTION OF LYSIS OF RENAL CELL CARCINOMA AND OTHER  
TUMORS BY BISPECIFIC ANTIBODY  
REAGENTS USING NATURAL KILLER NK CELLS  
TCR-ALPHA-BETA AND TCR-GAMMA-DELTA CTL AS  
EFFECTOR CELLS.

AUTHOR(S): BOLHUIS R L H [Reprint author]; SEGAL D; VAN DIJK J;  
WARNAAR S; LAMERS C M J

CORPORATE SOURCE: DEP IMMUNOL, DANIEL DEN HOED CANCER CENT, ROTTERDAM, NETH

SOURCE: Proceedings of the American Association for Cancer Research

Annual Meeting, (1989) Vol. 30, pp. 376.

Meeting Info.: EIGHTIETH ANNUAL MEETING OF THE AMERICAN  
ASSOCIATION FOR CANCER RESEARCH, SAN FRANCISCO, CALIFORNIA,  
USA, MAY 24-27, 1989. PROC AM ASSOC CANCER RES ANNU MEET.

ISSN: 0197-016X.

DOCUMENT TYPE: Conference; (Meeting)

FILE SEGMENT: BR

LANGUAGE: ENGLISH

ENTRY DATE: Entered STN: 22 Aug 1989

Last Updated on STN: 22 Aug 1989

## 1491

Relationships Between Survival and Specific Host Defenses Assayed *Ex Vivo* Using a Curative Protocol of Adriamycin and Interleukin 2. R.L.X. Ho, P. Ujhazy, M.J. Ehrke and E. Mihich, Grace Cancer Drug Center, Roswell Park Memorial Institute, Buffalo, NY 14263.

Treatment with Adriamycin (ADM, 6 mg/kg, i.v., Days 1 and 8) plus Interleukin 2 (IL2, 250U, i.p., bid, Days 9-40) increases the mean survival time of tumor (5 x 10<sup>4</sup> EL4 cells, i.p., Day 0) bearing C57BL/6 mice from 14 ± 2 days to > 60 days. This protocol was developed to exploit not only direct tumor cytotoxicity but also drug-induced immunomodulations identified in previous studies. In fact, the 60 day survivors can resist rechallenge by the same tumor indicating that a long-lasting immunity has been induced. Using this model of local administration of low dose IL2 in a chemotherapeutic protocol, the role of host antitumor defenses assayed *ex vivo* in relation to the *in vivo* measure of survival after inoculation of this weakly immunogenic tumor has been examined. Antitumor effector activities (natural killers, lymphokine activated killers with and without further *in vitro* stimulation by IL2, cytotoxic T lymphocytes, splenic macrophages, adherent and non-adherent peritoneal exudate cells) of mice treated in parallel with those in survival studies are measured at three time points during tumor progression. Data from these *ex vivo* assays show high correlation between elevated immune responses *ex vivo* and the treatment of the tumor bearing mice with ADM and/or IL2. These data are being analyzed to identify *ex vivo* assayable predictors of survival. Such predictors could be effectively used in monitoring therapeutic response and designing optimal protocols. (Supported in part by CA15142, CA24538, NCI USPHS and the gift of IL2 from DuPont.)

## 1492

The induction of lysis of renal cell carcinoma and other tumors by bispecific antibody reagents using natural killer (NK) cells TCRαβ and TCRγδ CTL as effector cells.

R.L.H. Bolhuis\*, D. Segal\*, J. van Dijk\*\*, S. Varnaar\*\* and C.M.J. Lamers\*

\* Dept. of Immunology, Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; # Dept. of Experimental Immunology, National Cancer Institute, Bethesda, U.S.A.; \*\* Dept. of Pathology, State University Leiden, Leiden, the Netherlands.

We have characterized TCR/CD3<sup>+</sup> TCRαβ<sup>+</sup>/CD3<sup>+</sup> and TCRγδ<sup>+</sup>/CD3<sup>+</sup> CTL phenotypically and functionally. These populations are clearly distinct on the basis of their TCR gene rearrangements. This is also reflected by MHC-restricted regulatory and cytolytic functions. We have researched the regulation of lytic activity by the CD2,3,16 and framework TCRαβ and TCRγδ effector cell surface molecules. We have made use of bispecific antibody reagents recognizing activation sites on the effector cells on the one hand and (tumor) target associated antigens on the other. The results suggest that multi-chain activation processes are involved and that additional target cell "specific" structures play a role in interactions with retargeted cloned effector cells. The distinct effector cell types show differential activation states depending on the "CD" specificity of the bispecific reagents.

## 1493

Augmentation of antitumor effects of intraperitoneal (ip) interleukin-2 (IL-2) by monoclonal antibodies (MoAbs) and cyclophosphamide (CY). A.M.M. Eggermont<sup>1</sup> and P.H. Sugarbaker<sup>2</sup>. Depts. of Surgical Oncology, Rotterdam Cancer Institute<sup>1</sup>, 3075 EA Rotterdam, the Netherlands; Winship Cancer Center<sup>2</sup>, Emory University, Atlanta, GA 30322, USA.

The incubation of murine splenocytes in IL-2 gives rise to lymphokine activated killer (LAK) cells, which can lyse fresh tumor cells. Toxicity of IL-2 *in vivo* is high. Therefore ways to augment the antitumor effects of tolerable doses of IL-2 must be explored. We investigated the effects of MoAbs on LAK cytotoxicity *in vitro* and the use of CY in combination with IL-2 ± LAK *in vivo* in the treatment of established (day 3) ip tumor.

MoAbs: We have previously shown that *in vivo* induction of LAK by ip IL-2 is much higher in peritoneal exudate cells (PEC) than in splenocytes (SPL). Antibody dependent cellular cytotoxicity (ADCC) by *in vivo* generated LAK was investigated by administering C<sub>3</sub>H mice (H-2k) 2x100 KU IL-2/day ip, for 3 days. PEC and SPL were harvested and after adding anti-H-2<sup>b</sup> or anti-H-2<sup>d</sup> MoAbs their cytotoxicity was assessed in 4hr <sup>51</sup>Cr-release assays with tumor targets MCA-105 (H-2<sup>b</sup>) and PB15 (H-2<sup>d</sup>). PEC-ADCC was ± 4 x higher than PEC-LAK lysis; SPL-ADCC and SPL-LAK were much lower.

Conclusion: MoAbs may be of particular interest for ip treatment regimens in combination with IL-2 ± LAK. CY: We investigated the value of combining CY (50 mg/kg, day 3) with low dose IL-2 (2x10 KU/day, ip, day 3-7) ± LAK (10<sup>6</sup>, ip, day 3) in the treatment of established ip tumor (MCA-105) in C57BL/6 mice. In all experiments CY+IL-2+LAK therapy was superior to any single agent or other combination therapy, as assessed by ip tumor load on day 14. Also significant survival benefits were achieved (25% cures) after combination therapy. Conclusion: CY significantly augments antitumor effects of IL-2 and LAK *in vivo*.

## 1494

A comparison of the *in vitro* properties of expanded lymphocytes from tumor draining lymph nodes (DLN) tumor infiltrating lymphocytes (TIL) and autologous peripheral blood lymphocytes (PBL). Y. Skornick, S. Topalian, S.A. Rosenberg, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

TIL have been used in immunotherapy trial and have shown encouraging therapeutic results in patients with Stage III melanoma. *In vitro*, many TIL populations derived from melanomas demonstrate lytic activity specific for the autologous tumor target, distinct from the non-specific activity of lymphokine activated killer cells (LAK). Regional or DLN are another source of lymphocytes which may be useful for immunotherapy. We have compared the *in vitro* properties of lymphocytes from DLN to autologous PBL and TIL grown from solid tumors from 10 patients; 2 melanomas, 4 breast carcinomas, 1 gastric cancer, 1 renal cancer 1 sarcoma and 1 lung carcinoma. PBL, TIL and DLN were grown in RPMI-10% human AB serum, 20% LAK cell culture supernatant, and 1000 u/cc rIL-2. Half of the cultures were restimulated with irradiated autologous tumor every 14 days (1:1 ratio). In all groups, tumor feeding enhanced proliferation. One melanoma TIL and DLN culture expanded for over 10 months. TIL and DLN proliferated longer and more rapidly than PBL. 8 of 10 early cultures of PBL, TIL and DLN contained greater or equal proportions of Leu-2<sup>+</sup> cells compared with Leu-3<sup>+</sup> cells. In long term cultures, an inversion of that ratio was seen. In short-term chromium release assays, specific lysis of autologous tumor was shown in tumor-fed TIL and DLN from 1 melanoma, 1 breast carcinoma and 1 lung carcinoma. Other cultures had non-specific lytic activity which usually correlated with Leu-19<sup>+</sup> positivity. Specific cytotoxicity against autologous tumor sometimes became apparent after prolonged culture and restimulation by autologous tumor. DLN have *in vitro* properties similar to TIL and may offer a useful immune reagent for cancer therapy.

BEST AVAILABLE COPY